Urine for urogenital targets
Molecular testing from an appropriate genital specimen is used for infections such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium.
Know what your sample can actually tell you
One sample is simpler. The right sample is smarter.
An STI panel is not clinically meaningful just because it lists more targets. The infection, body site, specimen type, and test method all need to match.
CLIA-certified laboratory
Urine, blood & site-specific swabs
Secure results portal
More targets do not automatically mean more useful answers.
AllrangeKit publicly advertises a 13-in-1 multiplex PCR panel using one urine sample, including HSV-1, HSV-2, and Treponema pallidum (syphilis).
CDC diagnostic guidance for those infections describes different approaches: lesion testing or type-specific blood antibodies for HSV, and a two-test blood serology algorithm for presumptive syphilis diagnosis.
Side-by-side
Compare the testing approach
This comparison uses the companies' publicly available product information and CDC guidance—not marketing shorthand.
| Category | AllrangeKit 13-in-1 | Better Life Science | Why it matters |
|---|---|---|---|
| Collection | One-specimen model One urine sample is marketed for 13 targets. |
Clinically matched Urine, blood, oral swabs, and rectal swabs are used according to the analyte and collection site. |
Urine is useful for specific urogenital infections, but it is not a universal specimen for every STI or every exposure site. |
| HSV-1 & HSV-2 | HSV-1 and HSV-2 are included in a urine multiplex PCR panel. | Better Life Science offers type-specific HSV-1 and HSV-2 antibody testing from blood. A fresh lesion should be evaluated by a healthcare provider for lesion-based testing. | CDC says active lesions should be confirmed with type-specific NAAT or culture from the lesion. Without lesions, type-specific serology can aid diagnosis. CDC does not describe urine PCR as the standard diagnostic approach for genital HSV. |
| Syphilis | T. pallidum is included in the urine multiplex PCR panel. | Better Life Science uses blood-based treponemal antibody testing with RPR and confirmatory treponemal reflex testing when indicated. | CDC states that a presumptive syphilis diagnosis requires both a treponemal and a nontreponemal serologic test. Direct molecular testing may be used by some labs on lesion material or tissue. |
| Oral & rectal exposure | The current 13-in-1 panel is marketed as urine-only. | Better Life Science offers oral and rectal swab testing for chlamydia and gonorrhea, in addition to genital testing. | A urine sample does not physically sample the throat or rectum. CDC screening recommendations call for testing at sites of sexual contact for appropriate populations. |
| Target relevance | The 13-target count includes U. parvum, U. urealyticum, and M. hominis. | Routine STD Hero panels focus on infections with clearer clinical testing and management pathways. | CDC's cervicitis guidance states that testing for U. parvum, U. urealyticum, and M. hominis is not recommended. |
| HIV & hepatitis | HIV screening is listed as "coming soon" and is not part of the current 13-in-1 urine panel. Hepatitis B and C are not listed in that panel. | STD Advanced includes blood-based HIV and syphilis testing. Ultimate Hero adds hepatitis B surface antigen, hepatitis C antibody, and both HIV 4th-generation Ag/Ab and HIV RNA PCR. | A high target count can still omit serious infections that require blood-based testing. |
Public offerings and prices can change. Comparison reviewed August 6, 2026. AllrangeKit is a trademark of its respective owner and is not affiliated with Better Life Science.
The Better Life Science standard
Right infection. Right site. Right sample.
Convenience matters—but specimen selection is part of the science, not an inconvenience to engineer away.
Blood for systemic markers
Blood is used when the clinically relevant marker is an antigen, antibody, or circulating viral target—including HIV, syphilis, hepatitis, and HSV antibodies.
Swabs for exposed sites
Oral and rectal swabs test the body sites actually exposed. A genital urine result does not answer whether chlamydia or gonorrhea is present in the throat or rectum.
Read the guidance yourself
What the CDC actually says
We encourage patients to look beyond a panel's target count and review the collection method behind each result.
PCR is a powerful technology. But technology does not make every specimen equally appropriate for every infection.
Genital herpes
When genital lesions are present, CDC recommends confirming the diagnosis with type-specific virologic testing from the lesion by NAAT or culture. Type-specific serologic testing can aid diagnosis when lesions are absent.
Read CDC herpes guidance →Syphilis
CDC states that presumptive diagnosis requires two blood-based serologic tests: one nontreponemal test and one treponemal test. Using only one type is insufficient.
Read CDC syphilis guidance →Testing the site of contact
CDC screening recommendations include urethral, rectal, and pharyngeal testing at sites of sexual contact for appropriate populations. The specimen should match the anatomy and exposure.
Read CDC screening recommendations →Ureaplasma and M. hominis
CDC's urethritis and cervicitis guidance says testing for U. parvum, U. urealyticum, and Mycoplasma hominis is not recommended in the cervicitis evaluation it describes.
Read CDC urethritis and cervicitis guidance →Choose useful answers
Find the panel that fits your needs
Start with the infections and exposure sites that matter—not the biggest number on the box.
Focused genital screening
STD Common
- Chlamydia, gonorrhea, trichomoniasis, and MGen
- Genital, two-site, and three-site options
- Molecular testing with clinically matched specimens
Most comparable choice
STD Advanced
- Chlamydia, gonorrhea, trichomoniasis, and MGen
- Blood-based HIV and syphilis testing
- Urine and blood collection matched to the target
Type-specific blood antibodies
Herpes Test
- HSV-1 and HSV-2 antibody testing
- Pain-free at-home blood collection
- A testing approach described by CDC when lesions are absent and serology is clinically appropriate
Broadest clinically relevant panel
Ultimate Hero
- Genital, oral, rectal, and blood-based testing
- HIV Ag/Ab plus HIV RNA PCR
- Syphilis, hepatitis B, and hepatitis C
Questions worth asking
Before you order
Does "multiplex PCR" automatically mean every target is clinically useful?
No. Multiplex PCR can detect several genetic targets in one run, but each result still depends on the assay's validation, specimen type, collection site, timing, and the clinical meaning of detecting that organism.
Is urine the CDC-recommended way to diagnose genital herpes?
CDC guidance describes type-specific NAAT or culture from an active lesion. When lesions are absent, type-specific blood antibody testing may aid diagnosis in appropriate situations. CDC does not describe urine PCR as the standard diagnostic approach for genital herpes.
Is urine the standard way to diagnose syphilis?
No. CDC states that presumptive syphilis diagnosis requires both a nontreponemal and a treponemal serologic test. Direct molecular testing may be performed by some laboratories on lesion exudate or tissue, but that is different from routine urine-only screening.
Why would I need an oral or rectal swab?
Chlamydia and gonorrhea can infect the throat or rectum independently of the genital tract. If those sites were exposed, a site-specific swab may be needed because a urine sample does not collect material from the throat or rectum.
Does a CLIA-certified laboratory make every test method equivalent?
CLIA certification is important and governs laboratory quality requirements. It does not mean that different specimens or testing algorithms answer the same clinical question. Ask any laboratory what specimen it uses, how the method was validated, and how the result should be interpreted.
Don't settle for more targets. Choose more meaningful testing.
Science you trust. Privacy you deserve.
Educational notice: This content is for general educational purposes and does not diagnose, treat, or replace advice from a healthcare provider. Test selection and interpretation depend on symptoms, exposure, timing, medical history, and applicable clinical guidance.
Comparison notice: Competitor information is based on public pages available on August 6, 2026. No statement on this page is intended to determine the analytical validity of an individual laboratory-developed test. It compares publicly described specimen and testing approaches with CDC guidance.
